OncoMatch/Clinical Trials/NCT03340506
Dabrafenib and/or Trametinib Rollover Study
Is NCT03340506 recruiting? Yes, currently enrolling (May 2026). This Phase 4 trial studies multiple treatments including dabrafenib and trametinib for melanoma.
Treatment: dabrafenib · trametinib — This study is to provide access for patients who are receiving treatment with dabrafenib and/or trametinib in a Novartis-sponsored Oncology Global Development, Global Medical Affairs or a former GSK-sponsored study who have fulfilled the requirements for the primary objective, and who are judged by the investigator as benefiting from continued treatment in the parent study as judged by the Investigator at the completion of the parent study.
Check if I qualifyExtracted eligibility criteria
Cancer type
Melanoma
Small Cell Lung Cancer
Tumor Agnostic
Glioblastoma
Prior therapy
Must have received: dabrafenib and/or trametinib (dabrafenib, trametinib) — within a Novartis or former GSK sponsored study
currently receiving treatment with dabrafenib/trametinib monotherapy or combination within a Novartis or former GSK sponsored study
Cannot have received: dabrafenib and/or trametinib (dabrafenib, trametinib)
previously permanently discontinued from study treatment in the parent protocol
Structured fields extracted by AI. May contain errors — verify against the official protocol.
US trial sites
- Honor Health Research Institute · Scottsdale, Arizona
- Honor Health Research Institute · Scottsdale, Arizona
- National Institute Of Health · Bethesda, Maryland
- James Cancer Hospital and Solove Research Institute Ohio State · Columbus, Ohio
- Mary Crowley Cancer Research · Dallas, Texas
Showing up to 5 US sites. See all sites on ClinicalTrials.gov →
Could you qualify for this trial?
Enter your biomarker results to see how this trial's eligibility criteria match your specific cancer profile.
Check if I qualify